Post-Transplant Cyclophosphamide Is Associated with Improved Overall Survival and Reduced Non-Relapse Mortality When Compared with Alemtuzumab in Patients Undergoing Allogeneic Transplantation with Reduced-Intensity Conditioning: A Single Center Retrospective Analysis

Key Points

• Overall survival improves with cyclophosphamide, compared to alemtuzumab, in allogeneic transplantation patients.
• Non-relapse mortality is lower in patients receiving cyclophosphamide, highlighting its potential effectiveness.
• This retrospective analysis evaluates a single center's data on treatment outcomes following transplantation.
• Findings may inform clinical practices regarding the choice of interventions for better patient survival.